E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA
Podcast this week about the recently published SELECT-GCA study, which evaluated the use of the janus kinase inhibitor upadacitinib (Rinvoq) for patients with new and relapsing GCA. Successful trial and an interesting topic. Paper itself here: https://www.nejm.org/doi/full/10.1056/NEJMoa2413449
--------
18:13
E122: Guidelines for Maybe Diagnosing HLH
This week I cover another of my newsletters, though I mostly use it as a skeleton to riff on a common (and challenging) issue for rheumatology consultants; diagnosing HLH. Check out the guidelines themselves here and have a listen to the podcast!
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00273-4/fulltext
--------
11:18
E121: Obinutuzumab in SLE-LN
Another day, another b cell podcast. Seems to be all the rage! This week I discuss the recently published NEJM trial of the anti CD20 agent obinutuzumab in lupus nephritis. Worth a read and listen, paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa2410965
--------
18:14
E120: Real Life Use of PEXIVAS-Low
What do you do when observational data and RCTs conflict? This week I'm covering the "real world PEXIVAS" study that was done by the French Vasculitis Study Group. Great read, interesting issues, have a listen and be sure to share with friends!
--------
24:33
E119: Teclistamab for Rheumatology Writ Large
One of my rare case-report podcasts, a topic that I typically avoid. The craze about CAR-T has also made me a little crazy, though, so I wanted to share what I think may be the ultimate destination for "more B cell depletion than rituximab" strategies.
Article: https://www.nejm.org/doi/full/10.1056/NEJMc2407150
Brasil